Zeptosens Company

Zeptosens is an ultra-sensitive microarray platform for quantitative proteomic investigations. It provides microarray platforms for sensitive and quantitative protein profiling, and signaling pathway analysis by reverse protein arrays. Its products include ZeptoREADER, a microarray reader for Zeptosens planar wave-guide technology; ZeptoMARK protein microarray chips and ZeptoCARRIER for various data points, which are split into arrays. The company also offers protein array services, including protein profiling for various samples, such as cell lines, tissues, microdissected cells, and depleted serums; and assay development.

In addition, it provides training services, technical and applications support, and technical service and maintenance. The company’s products are used in various applications, including biomarker/target discovery and validation, cell-based screening, mode of action profiling, selectivity profiling, and toxicology investigation. Its customers include pharma research and development companies, biotech companies, and academic institutions.

Zeptosens was founded in 1998 and is headquartered in Wilderswil, Switzerland.
Technology: P4 Medicine
Industry: Regenerative Medicine
Headquarters: Wilderswil, Bern, Switzerland
Founded Date: 6-20
Employees Number: 1001-5000
Funding Status: M&A
Investors Number: 2
Total Funding: CHF14M
Last Funding Type: Series B

Visit Website
Register and Claim Ownership